| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.47▲ | 3.47▲ | 3.55▲ | 1.29▲ | 1.36▲ |
| MA10 | 3.49▲ | 3.06▲ | 2.25▲ | 0.98▲ | 1.23▲ |
| MA20 | 2.79▲ | 2.03▲ | 1.51▲ | 0.90▲ | 2.19▲ |
| MA50 | 1.69▲ | 1.32▲ | 1.19▲ | 1.18▲ | 3.35▲ |
| MA100 | 1.32▲ | 1.23▲ | 1.20▲ | 2.56▲ | 6.57▼ |
| MA200 | 1.21▲ | 1.38▲ | 1.54▲ | 3.78▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | 0.195▲ | 0.322▲ | 0.233▲ | 0.125▲ |
| RSI | 77.712▲ | 78.111▲ | 81.104▲ | 89.900▲ | 57.974▲ |
| STOCH | 23.978 | 84.954▲ | 79.525 | 25.792 | 20.119 |
| WILL %R | -33.846 | -7.143▲ | -6.574▲ | -7.239▲ | -7.239▲ |
| CCI | 60.491 | 67.479 | 104.039▲ | 453.008▲ | 212.870▲ |
| ▲ RSI | $BDRX RSI(14) Crossed Above 70 | Set Alert |
| RSI | $BDRX RSI(14) Crossed Above 50 | Set Alert |
| ▲ MACD | $BDRX MACD(12,26,9) Crossed Above Zero | Set Alert |
| MA | $BDRX Price Crossed Above MA(50) | Set Alert |
| ▲ GAP | $BDRX Open Gap Up %5 | Set Alert |
| ▲ GAP | $BDRX Open Gap Up %3 | Set Alert |
| ▲ GAP | $BDRX Open Gap Up %2 | Set Alert |
| ▲ BREAK | $BDRX Price Breaks 60 Days High | Set Alert |
| ▲ BREAK | $BDRX Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $BDRX Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $BDRX Price Breaks 10 Days High | Set Alert |
|
Thursday, April 02, 2026 09:55 AM
eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor involved in cellular metabolism, growth, and proliferation and activated during tumorigenesis. mTOR has been ...
|
|
Thursday, April 02, 2026 06:51 AM
MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction ...
|
|
Monday, March 30, 2026 08:23 AM
BDRX READ THE FULL BDRX RESEARCH REPORT We are initiating coverage of Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) with a valuation of $7.00. Biodexa is a clinical-stage GI oncology company focused on ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 06/04/26 | 3.985 | 3.985 | 3.31 | 3.74 | 1,060,986 |
| 02/04/26 | 0.9235 | 1.35 | 0.8008 | 0.8733 | 119,820,625 |
| 01/04/26 | 0.614 | 0.6475 | 0.614 | 0.614 | 19,750 |
| 31/03/26 | 0.6099 | 0.6501 | 0.6006 | 0.6179 | 57,982 |
| 30/03/26 | 0.6804 | 0.6817 | 0.6005 | 0.6116 | 114,921 |
| 27/03/26 | 0.6603 | 0.69 | 0.65 | 0.6541 | 37,927 |
| 26/03/26 | 0.7071 | 0.7071 | 0.66 | 0.6603 | 57,210 |
| 25/03/26 | 0.68 | 0.7811 | 0.6745 | 0.691 | 81,047 |
| 24/03/26 | 0.654 | 0.6999 | 0.653 | 0.6601 | 36,180 |
| 23/03/26 | 0.68 | 0.7433 | 0.678 | 0.684 | 90,210 |
|
|
||||
|
|
||||
|
|